Clinical and metabolic features of the randomised controlled Diabetes Remission Clinical Trial (DiRECT) cohort
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Substantial weight loss in type 2 diabetes can achieve a return to non-diabetic biochemical status, without the need for medication. The Diabetes Remission Clinical Trial (DiRECT), a cluster-randomised controlled trial, is testing a structured intervention designed to achieve and sustain this over 2 years in a primary care setting to determine practicability for routine clinical practice. This paper reports the characteristics of the baseline cohort. People with type 2 diabetes for <6 years with a BMI of 27–45 kg/m2 were recruited in 49 UK primary care practices, randomised to either best-practice diabetes care alone or with an additional evidence-based weight management programme (Counterweight-Plus). The co-primary outcomes, at 12 months, are weight loss ≥15 kg and diabetes remission (HbA1c <48 mmol/mol [6.5%]) without glucose-lowering therapy for at least 2 months. Outcome assessors are blinded to group assignment. Of 1510 people invited, 423 (28%) accepted; of whom, 306 (72%) were eligible at screening and gave informed consent. Seven participants were later found to have been randomised in error and one withdrew consent, leaving 298 (176 men, 122 women) who will form the intention to treat (ITT) population for analysis. Mean (SD) age was 54.4 (7.6) years, duration of diabetes 3.0 (1.7) years, BMI 34.6 (4.4) kg/m2 for all participants (34.2 (4.2) kg/m2 in men and 35.3 (4.6) kg/m2 in women) and baseline HbA1c (on treatment) 59.3 (12.7) mmol/mol (7.6% [1.2%]). The recruitment rate in the intervention and control groups, and comparisons between the subgroups recruited in Scotland and England, showed few differences. DiRECT has recruited a cohort of people with type 2 diabetes with characteristics similar to those seen in routine practice, indicating potential widespread applicability. Over 25% of the eligible population wished to participate in the study, including a high proportion of men, in line with the prevalence distribution of type 2 diabetes. www.controlled-trials.com/ISRCTN03267836 ; date of registration 20 December 2013
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“observational follow-up of larger, longer, trials increasingly suggest benefits from substantial intentional weight loss, likely related to blood pressure control. 40,41”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [40]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The sample had characteristics very similar to the general population of people with type 2 diabetes, so the results are likely to be widely generalisable. 15”
The cited source says what the claim attributes to it.
In the citing paper
“These considerations, and the fact that DiRECT included a high proportion of participants from more socially deprived backgrounds 15 (unlike many other programs), all imply that the intervention should be widely transferable within routine healthcare.”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Baseline characteristics were similar between groups. 15”
From Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial (2019) · cites this paper as [15]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164 · cited 2×
“In the early years after diagnosis type 2 diabetes has been shown to be a reversible metabolic condition [1, 2].”
BackgroundResultSelf-citationAssociation of an intensive lifestyle intervention with remission of type 2 diabetes
Gregg, E. W., Chen, H., Wagenknecht, L. E., Clark, J. M., Delahanty, L. M., Bantle, J., Pownall, H. J., Johnson, K. C., Safford, M. M., Kitabchi, A. E., et al. (2012) · JAMA · doi:10.1001/jama.2012.67929 · Cited by 752
Treweek, S., Lockhart, P., Pitkethly, M., Cook, J. A., Kjeldstrøm, M., Johansen, M., Taskila, T. K., Sullivan, F. M., Wilson, S., Jackson, C., et al. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002360 · Cited by 623
Steven, S., Hollingsworth, K. G., Al-Mrabeh, A., Avery, L., Aribisala, B., Caslake, M., & Taylor, R. (2016) · Diabetes Care · doi:10.2337/dc15-1942 · Cited by 418
Self-citationMechanisms of Recovery From Type 2 Diabetes After Malabsorptive Bariatric Surgery
Guidone, C., Manco, M., Valera-Mora, E., Iaconelli, A., Gniuli, D., Mari, A., Nanni, G., Castagneto, M., Calvani, M., & Mingrone, G. (2006) · Diabetes · doi:10.2337/db06-0068 · Cited by 368
Do men develop type 2 diabetes at lower body mass indices than women?
on behalf of The Scottish Diabetes Research Network Epidemiology Group, Logue, J., Walker, J. J., Colhoun, H. M., Leese, G. P., Lindsay, R. S., McKnight, J. A., Morris, A. D., Pearson, D. W., Petrie, J. R., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2313-3 · Cited by 313
Self-citationPredicting the Glycemic Response to Gastric Bypass Surgery in Patients With Type 2 Diabetes
Dixon, J. B., Chuang, L.-M., Chong, K., Chen, S.-C., Lambert, G. W., Straznicky, N. E., Lambert, E. A., & Lee, W.-J. (2013) · Diabetes Care · doi:10.2337/dc12-0779 · Cited by 199
Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review
Leslie, W. S., Hankey, C. R., & Lean, M. E. J. (2007) · QJM · doi:10.1093/qjmed/hcm044 · Cited by 173 · cited 1×
“Almost a quarter of the entire cohort was prescribed antidepressant medications, some of which are associated with weight gain [11].”
BackgroundSelf-citation
Research works printed but not linked: 1
- Brierley L, McGurnaghan S, Blackbourn L, McKeigue PM, Colhoun HM (2017) The changing landscape of diabetes drug therapy in a national population of people with type 2 diabetes. Diabetologia 60(Suppl 1):A849 (Abstract)
Cited by
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095
Self-citationLean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30068-3 · Cited by 1,017
“Baseline characteristics were similar between groups.(15)”
MethodResultInfluentialSelf-citationTaylor, R., Al-Mrabeh, A., Zhyzhneuskaya, S., Peters, C., Barnes, A. C., Aribisala, B. S., Hollingsworth, K. G., Mathers, J. C., Sattar, N., & Lean, M. E. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.003 · Cited by 450
Self-citationLipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Opazo-Ríos, L., Mas, S., Marín-Royo, G., Mezzano, S., Gómez-Guerrero, C., Moreno, J. A., & Egido, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072632 · Cited by 363
Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Richter, B., Hemmingsen, B., Metzendorf, M.-I., & Takwoingi, Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012661.pub2 · Cited by 283
Metadata
- Authors
- Taylor, R., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Sattar, N., Welsh, P., Peters, C., Zhyzhneuskaya, S., Hollingsworth, K. G., Al-Mrabeh, A., Rodrigues, A. M., Rehackova, L., Adamson, A. J., Sniehotta, F. F., Mathers, J. C., Ross, H. M., McIlvenna, Y., Kean, S., Ford, I., McConnachie, A., & Lean, M. E. J.
- Affiliations
- Newcastle University (GB)
- Glasgow Royal Infirmary (GB)
- University of Glasgow (GB)
- Corresponding author
- Lean, Michael E. J.
- ORCID
- Taylor, Roy
- Leslie, Wilma S.
- Barnes, Alison C
- Brosnahan, Naomi
- Thom, George
- McCombie, Louise
- Sattar, Naveed
- Welsh, Paul
- Zhyzhneuskaya, Sviatlana
- Hollingsworth, Kieren G.
- Al-Mrabeh, Ahmad
- Rodrigues, Angela M.
- Rehackova, Lucia
- Adamson, Ashley J.
- Sniehotta, Falko F.
- Mathers, John C.
- Kean, Sharon
- Ford, Ian
- McConnachie, Alex
- Lean, Michael E. J.
- Venue
- Diabetologia
- Published
- 2017-11-30
- Volume
- 61
- Issue
- 3
- Pages
- 589-598
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC6448967
- OpenAlex
- W2769315987
- Cited by
- 55
- References
- 23
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 6 · 2023: 7 · 2022: 7 · 2021: 6 · 2020: 8 · 2019: 9 · 2018: 5 · 2017: 1
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Northumbria Research Link (Northumbria University) (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Diabetes UK (13/0004691)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetes remission, weight loss, weight management, primary care, HbA1c, obesity, recruitment (clinical trials), DIRECT
- MeSH terms
- Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, England, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Quality of Life, Scotland, Cohort Studies, Weight Loss, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical and metabolic features of the randomised controlled Diabetes Remission Clinical Trial (DiRECT) cohort. https://app.cochat.ai/papers/10.1007/s00125-017-4503-0
- The paper
- Taylor, R., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Sattar, N., Welsh, P., Peters, C., Zhyzhneuskaya, S., Hollingsworth, K. G., Al-Mrabeh, A., Rodrigues, A. M., Rehackova, L., Adamson, A. J., Sniehotta, F. F., Mathers, J. C., Ross, H. M., McIlvenna, Y., . . . Lean, M. E. J. (2018). Clinical and metabolic features of the randomised controlled Diabetes Remission Clinical Trial (DiRECT) cohort. Diabetologia. https://doi.org/10.1007/s00125-017-4503-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
